Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-cash Items (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Non-cash Items for 6 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items fell 98.15% to $6.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.7 million, a 98.15% decrease, with the full-year FY2025 number at $6.7 million, down 98.15% from a year prior.
  • Non-cash Items was $6.7 million for Q4 2025 at Janux Therapeutics, down from $6.8 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $361.6 million in Q4 2024 to a low of $5.0 million in Q1 2022.
  • A 5-year average of $74.6 million and a median of $16.7 million in 2023 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: soared 2060.97% in 2024, then tumbled 98.15% in 2025.
  • Janux Therapeutics' Non-cash Items stood at $63.0 million in 2021, then tumbled by 52.65% to $29.8 million in 2022, then tumbled by 43.86% to $16.7 million in 2023, then skyrocketed by 2060.97% to $361.6 million in 2024, then crashed by 98.15% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Non-cash Items are $6.7 million (Q4 2025), $6.8 million (Q3 2025), and $6.5 million (Q2 2025).